Flare Therapeutics

Flare Therapeutics is a privately held Cambridge, Massachusetts company that says it works only on drugging transcription factors, with a chemistry and proteomics engine for finding ligands directly in cells. The company says its pipeline is initially focused on precision oncology. FX-909 is described as a first-in-class oral small-molecule inhibitor of PPARG, the master regulator of the luminal lineage, in a randomised Phase 1b study in PPARG-high locally advanced or metastatic urothelial cancer (NCT05929235, sponsored by Flare, active and not recruiting; one arm adds pembrolizumab). FX-111 is described as a degrader of the transcriptionally active, hormone-bound androgen receptor (AR ON) and is in a Phase 1 study in metastatic castration-resistant prostate cancer (NCT07719361, recruiting). The company also names a partnership with Roche. Third Rock Ventures lists Flare under its Cancer focus and gives 2021 as its year of investment.